G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022

Rhea-AI Summary

G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call for a corporate and financial update on August 3, 2022, at 8:30 a.m. ET. This event marks an opportunity for investors to gain insights into the company’s current performance and future outlook.

G1 Therapeutics focuses on developing therapies for cancer, with its first product, COSELA® (trilaciclib), aimed at improving patient outcomes across various solid tumors.

Positive

• G1 Therapeutics remains focused on advancing its clinical pipeline in oncology, which may drive future growth.
• COSELA® is positioned as a next-generation therapy, enhancing the company's market potential.

Negative

• None.

RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET.

Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo and COSELA^® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com

FAQ

When is G1 Therapeutics' Q2 2022 financial update conference call?

G1 Therapeutics' Q2 2022 financial update conference call is scheduled for August 3, 2022, at 8:30 a.m. ET.

What is the focus of G1 Therapeutics?

G1 Therapeutics focuses on developing and commercializing therapies to improve the lives of cancer patients, with COSELA® as its first commercial product.

How can I access G1 Therapeutics' conference call?

Investors can register to receive dial-in details for the conference call through the company's provided link.

What is COSELA® and its significance for G1 Therapeutics?

COSELA® (trilaciclib) is G1 Therapeutics' first commercial product, aimed at improving patient outcomes in various solid tumors.